FIG 9.
Analysis of ALV and CsA sensitivities of engineered rEAV ALV-resistant mutants. Huh7 cells in 96-well plates were infected with rEAVwt (control) and rEAV ALV-resistant mutants (MOI, 0.05), grouped per ALV replicate, in the presence of 0 to 50 μM ALV (A and B) or CsA (C and D). Cells were incubated for 3 days and cell viability was monitored using a commercial assay. The cytotoxicity of ALV or CsA treatment only was monitored in parallel in mock-infected Huh7 cells (light gray line). Graphs show the results (average and SD) of a representative experiment that was performed in quadruplicate. All experiments were repeated at least twice.